Skip to main content
Premium Trial:

Request an Annual Quote

Eidogen and Sertanty Merge

NEW YORK, March 11 (GeneWeb News) - Cheminformatics provider Sertanty and structural informatics company Eidogen -- both privately held firms -- said earlier this week that they have merged to become Eidogen-Sertanty.

Steven Muskal, founder and CEO of Sertanty, is CEO of the new company, and Derek Debe, founder and CEO of Eidogen, has assumed the role of CSO.

The combined firm will offer "a unique suite of software, content, and discovery services encompassing both structural and chemical informatics," said Debe in a statement.

Sertanty provides kinase family structure-activity databases and the Lucia cheminformatics platform, while Eidogen offers TIP (Target Informatics Platform), which manages target sequence and structure information, enables sequence-to-structure generation and systematic annotation of ligand binding sites, and establishes N-by-N correlations between targets at the levels of sequence, structure, binding site and receptor-ligand interaction.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.